Clinical Trial

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 1, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected deleterious mutations in genes involved in homologous recombination repair (HRR) or homologous recombination deficiency identified by whole genome sequencing
Trial Details
NCT Number NCT06237205
Lead Sponsor Korea University Anam Hospital
Collaborators: Takeda, Korean Cancer Study Group
Conditions Efficacy
Enrollment 33 participants
Start Date 2024-02-27
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-01